Mode
Text Size
Log in / Sign up

Hepatic vein occlusion with portal vein embolization yields 24.5% greater future liver remnant increaseNew surgical techniques show larger liver growth before surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that hepatic vein occlusion combined with portal vein embolization provides a significantly greater hypertrophy response.

This meta-analysis evaluated surgical strategies for patients undergoing 2-stage hepatectomy who presented with insufficient future liver remnant volume. The study included a large sample size of 5,891 patients to evaluate the efficacy of different surgical interventions in promoting liver hypertrophy prior to definitive resection.

The primary intervention analyzed was hepatic vein occlusion combined with portal vein embolization, which was compared against portal vein embolization alone. Additionally, the study evaluated the impact of associating liver partition and portal vein ligation for staged hepatectomy as a strategy to increase future liver remnant volume.

Regarding the primary outcome, hepatic vein occlusion combined with portal vein embolization resulted in a mean increase of 36.8% in the future liver remnant. When compared directly to portal vein embolization alone, the combination of hepatic vein occlusion and portal vein embolization showed a significantly greater increase in future liver remnant, with a mean difference of 24.5% (P <.01). Furthermore, the strategy of associating liver partition and portal vein ligation was associated with a substantial mean increase of 68.5% in the future liver remnant.

Secondary outcomes included the feasibility of stage 2 procedures and overall morbidity and mortality. The feasibility of stage 2 using hepatic vein occlusion combined with portal vein embolization was reported at 78%, while the feasibility of stage 2 using associated liver partition and portal vein ligation was higher, at 95%. When comparing morbidity and mortality between the strategy of associating liver partition and portal vein ligation versus other surgical strategies, no significant difference was observed.

Safety and tolerability data were not specifically reported for individual adverse events or serious complications. However, the analysis indicates that while hepatic vein occlusion combined with portal vein embolization provides a more pronounced hypertrophy response than portal vein embolization alone, there was no clear advantage in second-stage feasibility observed for the combination of hepatic vein occlusion and portal vein embolization compared to portal vein embolization alone.

These results suggest that combining techniques may offer superior volume gains for patients with insufficient liver volume. The high mean increase of 68.5% seen with liver partition and portal vein ligation suggests a potent hypertrophy response, though the lack of significant difference in morbidity and mortality between these strategies indicates that the additional complexity may not significantly compromise patient safety in this cohort.

Methodological limitations include the fact that the analysis was limited by the available data provided in the included studies. Because this is a meta-analysis of both noncomparative and comparative studies, the results should be interpreted as associations rather than direct causal links. Clinical implications suggest that for patients requiring significant hypertrophy, combined techniques like hepatic vein occlusion with portal vein embolization or liver partition with portal vein ligation may provide superior outcomes compared to single-modality interventions. However, clinicians must weigh these findings against individual patient factors and the specific surgical context of each case.

For patients facing major liver cancer, the success of surgery often depends on how much healthy liver tissue remains after a tumor is removed. In many cases, the remaining liver might be too small to support the body's needs. To solve this, surgeons use specific techniques to encourage the liver to grow before the final stage of surgery. This research looks at different ways to achieve that growth and helps doctors decide which methods provide the best results for their patients.

the researchers conducted a meta-analysis, which is a large-scale review of existing data from many different studies. They looked at data from 5,891 patients undergoing a two-stage surgery called a hepatectomy. These are patients whose liver volume was initially considered insufficient to survive the operation without extra help. The study compared several methods, including blocking certain veins and arteries to stimulate growth.

The findings show that combining hepatic vein occlusion with portal vein embolization led to a significant increase in the size of the remaining liver. Specifically, this combination showed a much larger growth response compared to using portal vein embolization alone. Another method—combining liver partition and portal vein ligation—showed even higher rates of growth, with an average increase of over 68 percent. These numbers suggest that these specific combinations are effective at making the liver larger before the final surgery.

While these techniques are effective at growing the liver, the study did not find a significant difference in overall safety or mortality rates between the different methods. This means that while one method might grow the liver more than another, both appear to be manageable for the patients involved. However, it is important to note that while one specific combination showed better growth, it did not show a clear advantage in the ease of completing the second stage of surgery compared to other methods.

It is important to remember that this was a meta-analysis, which means it summarizes existing data rather than testing a new treatment on new patients. Because the results are based on a collection of different studies, there may be variations in how these techniques were performed across different hospitals. Patients should not view this as a guaranteed outcome for their specific case, as every patient's health and anatomy are unique.

For patients right now, this research provides evidence that advanced surgical combinations can successfully increase liver size before major surgery. It gives surgeons more confidence in using these specific techniques to improve the chances of a successful recovery. Patients should discuss these specific methods with their surgical team to see if these advanced techniques are appropriate for their individual treatment plan.

What this means for you:
Combining specific vein and artery blocks can significantly increase liver growth before major cancer surgery.

Study Details

Study typeMeta analysis
Sample sizen = 5,891
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Insufficient future liver remnant volume remains a critical challenge in 2-stage hepatectomy. This meta-analysis aimed to evaluate the outcome in distinct 2-stage hepatectomies with a focus on hepatic vein occlusion combined with portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy. METHODS: A systematic literature search was conducted in MEDLINE (PubMed) up to December 2024. Comparative and noncomparative studies were included. The primary outcome was the observed increase in future liver remnant. Secondary outcomes included feasibility of stage 2, morbidity, and mortality. RESULTS: The meta-analysis included 103 studies (5,891 patients). Noncomparative hepatic vein occlusion combined with portal vein embolization studies showed a mean future liver remnant increase of 36.8%. Compared with portal vein embolization, hepatic vein occlusion combined with portal vein embolization resulted in a significantly greater future liver remnant increase (mean difference 24.5%, P < .01) despite a smaller initial future liver remnant volume. The feasibility of stage 2 was 78% after hepatic vein occlusion combined with portal vein embolization and similar to portal vein embolization alone. Associating liver partition and portal vein ligation for staged hepatectomy demonstrated a substantial mean future liver remnant increase (68.5%) and a high stage 2 feasibility rate (95%). Morbidity and mortality rates following associating liver partition and portal vein ligation for staged hepatectomy were not significantly different from those of portal vein embolization and hepatic vein occlusion combined with portal vein embolization. CONCLUSION: Hepatic vein occlusion combined with portal vein embolization was associated with a more pronounced hypertrophy response compared with portal vein embolization in terms of future liver remnant growth, although a clear advantage in second-stage feasibility was not observed. Within the limitations of the analyzed data, associating liver partition and portal vein ligation for staged hepatectomy was associated with the highest future liver remnant increase and completion rates, whereas mortality rates showed no statistically significant difference compared with other strategies. Careful patient selection and further prospective studies are warranted to define the optimal role of hepatic vein occlusion combined with portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in 2-stage hepatectomy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.